These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Letter to the Editor. Differences between lentiviral vector-mediated ex vivo hematopoietic stem cell and adeno-associated virus gene therapies for neurological disorders. Carbonaro-Sarracino DA; LeWinter R; Meltzer L J Neurosurg; 2022 May; 136(5):1501. PubMed ID: 34891135 [No Abstract] [Full Text] [Related]
9. Gene therapy using haematopoietic stem and progenitor cells. Ferrari G; Thrasher AJ; Aiuti A Nat Rev Genet; 2021 Apr; 22(4):216-234. PubMed ID: 33303992 [TBL] [Abstract][Full Text] [Related]
10. Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper-IgM syndrome. Vavassori V; Mercuri E; Marcovecchio GE; Castiello MC; Schiroli G; Albano L; Margulies C; Buquicchio F; Fontana E; Beretta S; Merelli I; Cappelleri A; Rancoita PM; Lougaris V; Plebani A; Kanariou M; Lankester A; Ferrua F; Scanziani E; Cotta-Ramusino C; Villa A; Naldini L; Genovese P EMBO Mol Med; 2021 Mar; 13(3):e13545. PubMed ID: 33475257 [TBL] [Abstract][Full Text] [Related]
11. A new simplified clarification approach for lentiviral vectors using diatomaceous earth improves throughput and safe handling. Labisch JJ; Bollmann F; Wolff MW; Pflanz K J Biotechnol; 2021 Jan; 326():11-20. PubMed ID: 33301854 [TBL] [Abstract][Full Text] [Related]
12. A comparison of AAV-vector production methods for gene therapy and preclinical assessment. Davidsson M; Negrini M; Hauser S; Svanbergsson A; Lockowandt M; Tomasello G; Manfredsson FP; Heuer A Sci Rep; 2020 Dec; 10(1):21532. PubMed ID: 33299011 [TBL] [Abstract][Full Text] [Related]
13. Integrase-Defective Lentiviral Vectors for Delivery of Monoclonal Antibodies against Influenza. Michelini Z; Minkoff JM; Yang J; Negri D; Cara A; Hanson BJ; Salvatore M Viruses; 2020 Dec; 12(12):. PubMed ID: 33348840 [TBL] [Abstract][Full Text] [Related]
14. The TOP vector: a new high-titer lentiviral construct for delivery of sgRNAs and transgenes to primary T cells. Humes D; Rainwater S; Overbaugh J Mol Ther Methods Clin Dev; 2021 Mar; 20():30-38. PubMed ID: 33335945 [TBL] [Abstract][Full Text] [Related]
15. Immune Reconstitution After Gene Therapy Approaches in Patients With X-Linked Severe Combined Immunodeficiency Disease. Blanco E; Izotova N; Booth C; Thrasher AJ Front Immunol; 2020; 11():608653. PubMed ID: 33329605 [TBL] [Abstract][Full Text] [Related]
19. Viral vector platforms within the gene therapy landscape. Bulcha JT; Wang Y; Ma H; Tai PWL; Gao G Signal Transduct Target Ther; 2021 Feb; 6(1):53. PubMed ID: 33558455 [TBL] [Abstract][Full Text] [Related]
20. A Crippa S; Alberti G; Passerini L; Savoia EO; Mancino M; De Ponti G; Santi L; Berti M; Testa M; Hernandez RJ; Quaranta P; Ceriotti S; Visigalli I; Morrone A; Paoli A; Forni C; Scala S; Degano M; Staiano L; Gregori S; Aiuti A; Bernardo ME Mol Ther Methods Clin Dev; 2024 Sep; 32(3):101313. PubMed ID: 39282079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]